國家衛生研究院 NHRI:Item 3990099045/13587
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12189/12972 (94%)
造访人次 : 956209      在线人数 : 821
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13587


    题名: A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers
    作者: Tsai, H;Yang, S;Hsiao, C;Kao, H;Shan, Y;Lin, Y;Yen, C;Du, J;Hsu, C;Wu, I;Chen, L
    贡献者: National Institute of Cancer Research
    摘要: Background: Advanced gastric, pancreatic and biliary tract cancer patients have poor prognosis. Platinum, fluoropyrimidine, taxane, irinotecan, and gemcitabine used alone or in combination are commonly used for these patients. However, the overall survival (OS) of these patients is still less than 1 year. Further development of other combinational regimens is needed. Oxaliplatin, nab-paclitaxel and S-1 have been shown to be effective for advanced gastric, pancreatic and biliary tract cancers according to previous studies. However, the toxicity of combination of these three drugs is concerned. Therefore, we conducted a phase I dose-escalating study using biweekly nab-paclitaxel in combination with oxaliplatin and oral S-1/leucovorin as first-line treatment for advanced gastric, pancreatic and biliary tract cancers to evaluate the toxicity of this regimen. Methods: The dose of nab-paclitaxel was 150 mg/m 2 in D1. The dose of S-1/leucovorin was 35 mg/m 2 and 30 mg twice daily from D1 to D7. The dose of oxaliplatin was 60, 75 or 85 mg/m 2 in D1. A 3+3 design was used to escalate the dose of oxaliplatin. Dose-limiting toxicity (DLT) was observed in the first 2 cycles (4 weeks). The primary endpoint was to determine maximal tolerated dose (MTD) of oxaliplatin in this regimen. An expansion cohort was included at the MTD level. The secondary endpoints were overall response rate (ORR), progression free survival (PFS), OS and toxicities of this regimen. Results: A total of 19 patients were enrolled from June 2018 to November 2020. The median follow-up time was 12 (1.9-27.1) months. No DLT developed at dose levels 1 and 2. One patient at dose level 3 (oxaliplatin 85 mg/m 2) was given with 60 mg/m 2. Therefore, 4 patients received oxaliplatin of dose level 1 (60 mg/m 2). One patient developed DLT (grade 3 diarrhea) among 6 patients at dose level 3. The MTD of oxaliplatin was 85 mg/m 2. Another 6 patients were enrolled in the expansion cohort of MTD. The mean age of all patients was 53.8 (29-68) years old. Thirteen patients had pancreatic cancer, 4 patients had biliary tract cancer and 2 patients had gastric cancer. The mean number of cycles of treatment of all patients was 11.4 (3-51). Thirteen patients discontinued treatment and five of them were due to progressive disease. The other patients discontinued treatment due to adverse events (AE), or concern for the AE or further treatment plan by patient or investigator’s decision. The most common treatment-related grade 3/4 AEs were neutropenia (57.9%), diarrhea (21.1%), and febrile neutropenia (10.5%). The ORR of all patients was 57.9% with 50%, 61.5%, and 50% for gastric, pancreatic, and biliary tract cancer, respectively. The median PFS of all patients was 13.4 months (95% confidence interval: 12.5-not reached). The median OS was not reached yet. Conclusions: This phase I study demonstrated that the MTD of oxaliplatin is 85 mg/m 2 in combination with nab-paclitaxel and oral S-1/leucovorin as first-line treatment for advanced gastric, pancreatic, and biliary tract cancers. The toxicities are acceptable with a durable response. Further phase II study is warranted to evaluate the efficacy of this regimen.
    日期: 2021-07
    關聯: Annals of Oncology. 2021 Jul;32(Suppl. 3):S146-S147.
    Link to: http://dx.doi.org/10.1016/j.annonc.2021.05.195
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000670004200139
    显示于类别:[其他] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000670004200139.pdf125KbAdobe PDF175检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈